Safety Pharmacology Post Meeting Survey 2014

Transcription

1 Q1 Please enter your personal information below. (If you want to be included in the 2014 Annual Meeting survey for a chance to win $200, this information is REQUIRED) Answered: 132 Skipped: 14 Name: Company: Address: Address 2: City/Town: State: ZIP: Country: Address: Phone Number: % % % % % % % % % % 0 Q2 What is your area of employment? Answered: 132 Skipped: 14 Academic Government Pharmaceutical CRO Independent Academic 9.85% 13 1 / 30

2 Government Pharmaceutical CRO Independent 6.82% % % % 9 Total Respondents: 132 Q3 I attended the SPS Annual Meeting as an: Answered: 141 Skipped: 5 Attendee Exhibitor Student Attendee Exhibitor Student 80.14% % % 1 Total Respondents: 141 Q4 Please grade the following meeting lengths as most desirable(5) to least desirable (1) Answered: 142 Skipped: 4 Length: 3.5 days (1 day... 2 / 30

3 Length: 3 days (.5 day CE,... Length: 3 days (2.5 day mai... Length: 3 days (First day C... Length: 4 days (First day C... 3 / 30

4 Length: 4 day (First day C... 5 (Most desirable) 4 3 (Neutral) 2 1 (Least desirable) 5 (Most desirable) 4 3 (Neutral) 2 1 (Least desirable) Total Length: 3.5 days (1 day CE, 2.5 day main meeting) 31.45% % % % % Length: 3 days (.5 day CE, 2.5 day main meeting) 17.50% % % % % Length: 3 days (2.5 day main meeting, then.5 day CE) 5.26% % % % % Length: 3 days (First day CE, 2 day main meeting) 25.86% % % % % Length: 4 days (First day CE, 3 day main meeting) 13.33% % % % % Length: 4 day (First day CE, 2 day main meeting, one day focused technical workshop) 28.93% % % % % Q5 This year, we had two tracks of presentation. For this meeting size, was this the right number of tracks? Answered: 145 Skipped: 1 4 / 30

5 Just right (I had plenty o... Too much (I had difficul... Too little! Just right (I had plenty of choice to meet my needs) Too much (I had difficulty selecting which sessions to attend) Too little! 91.72% % % 5 Total 145 Q6 How long should the lunch break be during the Annual Meeting? Answered: 135 Skipped: 11 1 Hour 2 Hours 1 Hour 2 Hours 48.89% % 69 Total 135 Q7 Please rank the likelihood of your 5 / 30

6 organization attending a meeting in the following rth American locations Answered: 143 Skipped: 3 Austin, Texas Boston, Massachusetts Honolulu, Hawaii (or... Montreal, Quebec Nashville, Tennessee Orlando, Florida 6 / 30

7 San Francisco, California Washington, DC Likely Unsure Unlikely Likely Unsure Unlikely Total Austin, Texas 63.12% % % Boston, Massachusetts 86.43% % % Honolulu, Hawaii (or another Hawaiian island) 42.86% % % Montreal, Quebec 69.72% % % Nashville, Tennessee 55.71% % % Orlando, Florida 68.79% % % San Francisco, California 79.43% % % Washington, DC 86.33% % % Q8 Please rank the likelyhood of your organization attending a meeting in the following European locations Answered: 143 Skipped: 3 Barcelona, Spain 7 / 30

8 Brussels, Belgium London, Great Britain Madrid, Spain Milan, Italy Paris, France Rome, Italy Likely Unsure Unlikely 8 / 30

9 Likely Unsure Unlikely Total Barcelona, Spain 62.24% % % Brussels, Belgium 60.99% % % London, Great Britain 63.38% % % Madrid, Spain 59.44% % % Milan, Italy 59.86% % % Paris, France 65.25% % % Rome, Italy 61.27% % % Q9 Score the following in importance to your consideration of attending the Annual Meeting: (1 being the least important and 5 being the most important) Answered: 141 Skipped: 5 Scientific program Cutting-edge topics 9 / 30

10 Networking Applied scientific... Variety of scientific... Overall cost of meeting / 30

11 Overall cost of location Ease of travel Theoretical scientific... Exhibitor interactions Sales contacts 11 / 30

12 Sales contacts Safety Pharmacology Post Meeting Survey 2014 Location Distance to hotels Exhibitor Sponsored... Advanced continuing / 30

13 Continuing education... Basic continuing... Local attractions 1. (Least Important) (Most Important) 1. (Least Important) (Most Important) Total Scientific program 1.42% % % % % / 30

14 Cutting-edge topics 0.72% % % % % Networking 2.17% % % % % Applied scientific topics 1.44% % % % % Variety of scientific content 1.44% % % % % Overall cost of meeting (travel, hotel, registration, etc.) 3.65% % % % % Overall cost of location 3.60% % % % % Ease of travel 1.43% % % % % Theoretical scientific topics 2.86% % % % % Exhibitor interactions 8.76% % % % % Sales contacts 22.46% % % % % Location 8.70% % % % % Distance to hotels 2.90% % % % % Exhibitor Sponsored Sessions 6.52% % % % % Advanced continuing education topics 16.31% % % % % Continuing education Courses 17.02% % % % % Basic continuing education topics 27.66% % % % % Local attractions 21.90% % % % % Q10 Of the listed potential scientific topics below, which topics would you most be interested in seeing presented at the Annual Meeting? Answered: 143 Skipped: 3 CV System 14 / 30

15 CNS System Biomarkers in Safety... Early Safety Profiling an... Translational Safety... Integrative Pharmacology Clinical Safety... Disease Models Regulatory interactions... vel Instrumentat... Case Studies Integrative Physiology 15 / 30

16 Disease Areas (eg: Oncolog... Stem Cells in SP/Biologica... PD/PK relationships vel In Vitro Cell-based... New Therapeutic... Immune System In Silico Approaches/M... Renal System Clinical Development Transgenic Animal Models 16 / 30

17 Nanotechnology in Safety... GI System Liver System In Vitro 3D Microphysiol... Regulatory interactions... Advanced CNS CV System GI System Interested t Interested Interested t Interested Total Respondents CV System CNS System 95.62% % % % / 30

18 Biomarkers in Safety Pharmacology Early Safety Profiling and De-risking 93.98% % % % Translational Safety Pharmacology/Translational Medicines Integrative Pharmacology Clinical Safety Pharmacology Disease Models Regulatory interactions/partnerships vel Instrumentation & Technologies Case Studies Integrative Physiology Disease Areas (eg: Oncology, Diabetes, Neuroscience, Immunology) Stem Cells in SP/Biological Stem Cells PD/PK relationships vel In Vitro Cell-based Assays New Therapeutic Modalities (eg: Gene therapies, micro RNA, antibodies) Immune System In Silico Approaches/Modeling Renal System Clinical Development Transgenic Animal Models Nanotechnology in Safety Pharmacology GI System Liver System In Vitro 3D Microphysiological Systems 92.48% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % / 30

19 Regulatory interactions/partnerships Advanced CNS CV System GI System % % % % % % % % 0 1 Q11 Did you attend the Sunday evening Welcome Reception? Answered: 145 Skipped: % % 42 Total 145 Q12 Did you find the poster presentation and networking time to be sufficient? Answered: 145 Skipped: 1 19 / 30

20 78.62% % 31 Total 145 Q13 This year, the annual Members' meeting was held Wednesday morning. Did you attend this presentation? Answered: 144 Skipped: % % 62 Total 144 Q14 Did you visit the Exhibit Hall to meet with any of the Exhibitors? Answered: 145 Skipped: 1 20 / 30

21 97.24% % 4 Total 145 Q15 What was your purpose for visiting Exhibitors? Answered: 133 Skipped: 13 Conduct business as... Create or explore new... Socialize Conduct business as a result of an existing relationship Create or explore new business contacts Socialize 67.67% % % 73 Total Respondents: 133 Q16 What other companies or organizations 21 / 30

22 would you like to see Exhibit at the SPS Annual Meeting? Answered: 27 Skipped: 119 Q17 Did you attend any of the Exhibitor Sponsored Sessions? Answered: 145 Skipped: % % 33 Total 145 Q18 Please specify which session(s) you attended: Answered: 112 Skipped: / 30

23 ChanTest and WIL Research... ACEA Biosciences:... CorDynamics: Examining Dr... Data Sciences Internationa... Nanion Technologies... GE Healthcare: Human... Sophion: Cardiac... Data Sciences Internationa... Emka Technologies... Cellular Dynamics... Elsevier: Leverage Dru... ChanTest and WIL Research: The ABC s of IND s ACEA Biosciences: The Applications of xcelligence Cardio System and Stem Cell-Derived Cardiomyocytes for Cardiac Risk Assessment CorDynamics: Examining Drug Candidates for Pulmonary Arterial Hypertension: Ups and Downs of Multiple Animal Models Data Sciences International: DSI s 7th Annual Data Blast Nanion Technologies: Complementary Automated Patch Clamp, Extracellular Field Potential and Impedance Recordings of Stem Cells Allow Reliable Wholistic Cardio- or Neurotoxicity Prediction GE Healthcare: Human ESC-Derived Cardiomyocytes: Bridging Analytical Platforms for more Comprehensive Cardiac Safety Assessment Sophion: Cardiac Electrophysiology: Update on CiPA and the Industry s Approach to Ion Channel Testing Data Sciences International: New Technologies to Refine Safety Pharmacology and Toxicology Studies Emka Technologies: Impact of Autonomic Nervous System on QT-RR Variability and Arrhythmia Liability Cellular Dynamics International: New Techniques for MEA-based Interrogation of Human Stem Cell Derived Cardiomyocytes to Support CiPA and In-Vitro Safety Pharmacology Assays Elsevier: Leverage Drug Approval Precedents to Inform Preclinical and Clinical Development 24.11% % % % % % % % % % % / 30

24 Total Respondents: 112 Q19 How did you become aware of this session? Answered: 107 Skipped: 39 SPS blast SPS website SPS Final Program Exhibitor mailer or flyer Exhibitor promotion in... SPS blast SPS website SPS Final Program Exhibitor mailer or flyer Exhibitor promotion in their booth 40.19% % % % % 15 Total Respondents: 107 Q20 Did you attend the Monday morning Plenary Keynote Lecture? Answered: 139 Skipped: 7 24 / 30

25 77.70% % 31 Total 139 Q21 Did you attend any of the Oral Presentations? Answered: 140 Skipped: % % 11 Total 140 Q22 How would you rate the quality of the meeting for its cost? Answered: 141 Skipped: 5 25 / 30

26 Excellent Good Satisfactory Poor Excellent Good Satisfactory Poor 39.72% % % % 3 Total 141 Q23 Please expand on your rating selection above: Answered: 62 Skipped: 84 Q24 Do you plan to attend the 2015 Annual Meeting in Prague, Czech Republic? Answered: 141 Skipped: 5 26 / 30

27 Maybe Maybe 43.26% % % 49 Total 141 Q25 As a rule, SPS does not supply addresses of attendees. We have received requests from registered SPS exhibitors for access to attendee s. Would you be agreeable to receiving a limited number of s from SPS exhibitors given that attendees could opt out of receiving them during the annual meeting registration process? Answered: 140 Skipped: 6 27 / 30

28 75.00% % 35 Total 140 Q26 SPS creates and s an ENewsletter which features content relevant to the Annual Meeting along with advertisements from Exhibitors. Please rate the ENewsetter. Answered: 128 Skipped: 18 Excellent Good Satisfactory Poor (no label) (no label) (no label) (no label) Total Average Rating Excellent 87.50% % % % Good 82.35% % % % Satisfactory 63.64% % % % Poor 0.00% % % % Q27 What other scientific meetings do you attend in September and October that might affect your ability to attend the SPS Annual Meeting? Answered: 76 Skipped: / 30

29 Q28 Did you attend any CE Courses? Answered: 138 Skipped: % % 98 Total 138 Q29 Please list any suggestions you may have for CE courses that have not yet been offered at the SPS Annual Meeting: Answered: 30 Skipped: 116 Q30 Did you stay for the all day Update and Perspectives on Comprehensive In Vitro Proarrhythmia Assay (CIPA)? Answered: 139 Skipped: 7 29 / 30

30 61.87% % 53 Total 139 Q31 What additional services do you wish to see the Safety Pharmacology Society offer to its members? Answered: 29 Skipped: 117 Q32 Please feel free to write any additional comments here: Answered: 37 Skipped: / 30